Pioneering green chemistry for healthier lives
DMC Biotechnologies is a U.S. biomanufacturer seeking to transform how the world makes chemicals. Through the power of precision fermentation, we create sustainable, high-quality specialty chemical ingredients that minimize environmental impact and promote a healthier future. Our commitment to innovation and eco-friendly practices drives us to lead the industry in green chemical production.
OUR MISSION
DMC is revolutionizing the chemical industry through precision fermentation and synthetic biology . Our mission is to decarbonize chemical production, deliver more sustainable and naturally produced products, and improve the security of global supply chains. With our core technology, Dynamic Metabolic Control™, we simplify biology to enable predictable, robust, and highly efficient fermentation processes. DMC is transforming how the world makes chemicals, fostering a sustainable future for all.
OUR TEAM
Management team
Our management team has broad experience in fermentation, renewable chemicals, and process industries.
JOSH YELEN, CPA
CFO
With over twenty years of experience in executive-level finance, accounting, operations, and sales, Josh brings a wealth of knowledge and expertise to our team. He has worked across diverse industries, including technology, healthcare, and biotech. Throughout his career, Josh has held pivotal roles such as Chief Operating Officer (COO), Vice President of Sales, and Chief Financial Officer (CFO), giving him a comprehensive understanding of how finance intersects with every aspect of a business. Josh is a licensed CPA, a Certified Exit Planning Advisor (CEPA®), and holds an MBA, further showcasing his dedication to professional excellence and strategic financial planning.
RUSTY PITTMAN
VP, BD
Rusty Pittman has over 25 years of commercial experience in the chemical, building materials, and renewable energy industries. Rusty was previously with Elevance Renewable Sciences, Inc where he spent the last six years as VP/Head of Marketing and Business Development.
ERNESTO SIMON
VP, Bioengineering
Ernesto Simon has 20 years of experience in metabolic engineering and industrial biotech and has led the development of various precision fermentation-based products from bench to commercial scale. He has worked with a diverse range of synthetic biology companies including Evolva (now Lallemand), Firmenich (now dsm-firmenich), Conagen, and Cemvita.
MARCEL LUBBEN, Ph.D.
VP, Strategic Alliances
Successful clean chemistry executive with accomplishments across multiple technologies and markets.
Sunny Gilbert, Ph.D., CA-AM
SUNNY GILBERT, Ph.D., CA-AM
Sr. Director Collaborations/Project Management
Sunny Gilbert’s professional career has spanned the agriculture, pharma, and biotech fields, contributing to projects related to biotechnological advancements. Gilbert’s roles have involved leveraging her scientific expertise in biochemistry, molecular biology, and biotechnology and her skills in alliance management to contribute to fields as varied as crop protection, cancer diagnostics, and synthetic biology.
Immediately before joining DMC, Gilbert held a significant role as part of a team that focused on precision oncology and cancer diagnostics at ArcherDX. The company launched the first CDx to be approved for the detection of MET gene alterations and was eventually acquired by Invitae for $1.4 billion as part of an expansion into the precision oncology space.
TREVOR ROSENSOHN
Director, Downstream Processing
Trevor Rosensohn is a chemical engineer with extensive experience in development and scale-up of chemical purifications. Trevor has developed processes and products for a wide range of applications across multiple industries. Currently, as the Director of Downstream Processing at DMC, Trevor oversees the commercialization of all new products and ensures the successful transition of innovative products from development to market.
Drew Delorenzo, Ph.D.
Director of Upstream Bioprocess and Analytical Chemistry
DREW DELORENZO, Ph.D.
Director of Upstream Bioprocess and Analytical Chemistry
Dr. Drew DeLorenzo is a graduate of Washington University in St. Louis, where his work as an NSF graduate research fellow combined genetic engineering, microbiology, and waste plant material to produce renewable fuels and chemicals for a more sustainable future. He has since spent time both as a bench scientist advancing antibiotic alternatives, a team lead developing high-throughput automated workflows, and a pharmaceutical analytical chemist. He now directs the Analytical Chemistry and Upstream Bioprocess teams at DMC and leverages his diverse background to facilitate collaboration between departments. He has a passion for science, environmental conservation, travel, home improvement projects, and photography.
Founding Team
Our founding team are serial entrepreneurs and leaders in synthetic biology and fermentation.
Matt Lipscomb, Ph.D.
Founder
Dr. Lipscomb is a Founder of DMC, Inc. His career has included a range of development stages from early R&D to commercial deployment in a variety of sectors, including both industrial and pharmaceutical biotechnology. Previously, he was a founding employee of OPX Biotechnologies and served in various roles during his tenure there. His technical leadership supported multiple successful fundraising rounds totaling more than $60M. He provided project leadership on the execution of a successful Department of Energy (DOE) ARPA-E Electrofuels program ($6M) for the production of biodiesel from H2 and CO2. His technical expertise includes microbial fermentation, process development, process modeling, analytical chemistry, and techno economic analysis (TEA) of bio-based processes.
MIKE LYNCH MD, Ph.D.
Founder
Dr. Lynch is a Founder of DMC, Inc. He is also an Assistant Professor in the Biomedical Engineering and Chemistry Departments at Duke University. Previously, Mike was founder and CSO of OPX Biotechnologies, Inc. where he led development efforts resulting in the successful piloting and demonstration of technology for the production of 3-hydroxy propionic acid (a precursor to the large volume commodity chemical, acrylic acid) and fatty acids from sugars via fermentation utilizing engineered biocatalysts. At Duke, Dr. Lynch and his team have recently developed the Synthetic Metabolic Valve technology enabling dynamic metabolic control of microbial metabolism in the context of a standardized bioprocess.
Directors & investors
Our directors and investors are global leaders within the synthetic biology, chemicals, and ESG industries.
DOUG CAMERON
INDEPENDENT DIRECTOR
Doug brings more than 30 years of experience in the biotech industry and has deep knowledge of technology, commercialization, venture capital, and private equity. He earned a Ph.D. in Biochemical Engineering from MIT and has worked for Cargill, Khosla Ventures, and First Green Partners, among others.
JOŠKO BOBANOVIĆ
Director, Industrial Biotech Strategy
Joško Bobanović joined Sofinnova in 2010 as a partner focused on the industrial biotech strategy. He works on early stage deals in Europe and North America with applications in chemicals, agriculture, food, and materials. Prior to joining Sofinnova Partners, he was part of the investment team at iNovia Capital in Montreal, Canada. In addition to DMC’ board, Joško sits on the boards of Metgen, Comet Bio, DNA Script, Biosyntia, Pyrowave and Protera Biosciences. Before going into venture capital, he created an internet startup and a software company. He is a mentor at BIRD Incubator, which helps entrepreneurs in software, data analytics, artificial intelligence, and machine learning.
ROB VAN DER MEIJ
Director
Rob is a chemical engineer from Delft University in the Netherlands and has worked both in the corporate, strategy consulting and start-up world in chemicals, process and water technology. Rob has held business management positions with Akzo Nobel and Shell Chemicals, was a founder and CEO of KiOR in the US and worked as CEO for several other start-ups in chemicals and water technology. He is also an investor and has board roles in several start-ups.
ALASTAIR COOPER
Director
Alastair Cooper is a Senior Investment Director at ADM Capital with responsibility for Early Stage Investments. Alastair spent 18 years as an Investment Banker, 16 years of which were at Morgan Stanley, within the Equity Division, as a Managing Director based in London and Hong Kong. His responsibilities included Head of European Derivatives, Proprietary Trading and Head of Asian Equity. Upon leaving Morgan Stanley in 2002, Alastair completed the One Year Farming Course at the Royal Agricultural College and has managed his own mixed organic farm since. As an active private investor, Alastair has made a number of investments within renewable energy and agriculture. Alastair holds a BSc in Zoology from Exeter University, England.
OUR LOCATIONS
JOIN THE TEAM
AT DMC
Become part of a dynamic team driving innovation and sustainability in biotechnology.